The reverse split went into effect Sept. 22, according to a regulatory filing, sending HNSN shares down -13% to $4.35 apiece. The stock was trading at $4.26 per share in mid-morning activity today, down -3.0%.
Mountain View, Calif.-based Hansen in July won FDA 510(k) clearance for its Magellan 10Fr robotic catheter with indications for use in the peripheral vasculature.
The company won CE Mark approval for the catheter in April, and has been used in procedures in Australia, Germany and the U.K. since its approval.
In April, Hansen also said it won CE Mark approval in the European Union for a new, larger version of its Magellan robot-assisted surgery platform for use in treating peripheral artery disease.